ANALYTICAL CHEMISTRY AND STABILITY TESTING OF TREATMENT DRUGS

Release Date:  December 2, 1998

RFP AVAILABLE:  N01DA-9-8093

P.T.

National Institute on Drug Abuse

The development of medications for the treatment of drug addiction is a major
mission of the National Institute on Drug Abuse (NIDA).  NIDA prepares potential
treatment drugs for use in preclinical toxicology evaluation, pharmacological
studies and clinical trials.  The treatment drugs include both bulk drug
substances (e.g., GBR-12909, tropane analogs, UH-232, cyclazocine, indanamines,
etc.) and dosage forms (e.g., buprenorphine tablets, GBR-12909 capsules,
cyclazocine capsules, etc.).  These drugs are acquired by the Government from
private industry, Government contractors/grantees or independent investigators. 
In order to assure the identity, strength, quality and purity of these materials,
the Government has been performing quality control tests before using them in its
research and development trials.  NIDA is soliciting proposals from qualified
organizations having the capacity to carry out the development of analytical
methods, conduct quality control tests and dosage form preparation, and  perform
stability studies for compounds and dosage forms to be used in its medications
development program.  It is estimated that a three-year incrementally funded cost
reimbursement (completion) type contract will be awarded with two one year
options.

RFP No. N01DA-9-8093 will be available electronically on or about December 7,
1998 and may be accessed through the Internet at the following address: 
http://www.nida.nih.gov/RFP/RFPList.html.  Please note that the RFP for this
acquisition will be streamlined to include only the Work Statement, Deliverables
and Reporting Requirements, Special Requirements and Mandatory Qualifications,
Technical Evaluation Criteria, and other necessary Proposal Preparation
Instructions. All information required for the submission of an offer will be
contained in the electronic RFP package.  Following proposal submission and the
initial review process, offerors comprising the competitive range may be
requested to provide additional documentation to the Contracting Officer. 
Responses to the RFP will be due on or about January 21, 1999.  Any responsible
offeror may submit a proposal that will be considered by the Government.  This
advertisement does not commit the Government to award a contract.

INQUIRIES

Inquiries may be direct to:

Brenda O. Brooks
Contracts Management Branch
National Institute on Drug Abuse
5600 Fishers Lane, Room 10-49
Rockville, MD  20857
Telephone:  (301) 443-6677
FAX:  (301) 443-7595
Email:  bb76n@nih.gov


Return to Volume Index

Return to NIH Guide Main Index


Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS)
  USA.gov - Government Made Easy


Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.